Tokyo Biotech
Small Molecules, Big Data: The AI-Powered Future of Oral Obesity Therapies
PRISM BioLab and Receptor.AI Partner to Navigate the Undruggable PPI Landscape On March 12, 2026, Tokyo-based PRISM BioLab and U.S.-based TechBio firm Receptor.AI announced a strategic collaboration to build an integrated, AI-navigated drug discovery platform. This partnership aims to solve one of the most persistent challenges in pharmacology: the discovery of orally available small molecules…
